Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
about
Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistanceThe potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer.Curcumin: updated molecular mechanisms and intervention targets in human lung cancer.Association of activated c-Met with NRAS-mutated human melanomas.MET Exon 14 Skipping in Non-Small Cell Lung Cancer.Loss of YAP1 defines neuroendocrine differentiation of lung tumors.Special issue: "MET as actionable target in cancer therapy".Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.MET targeted therapy for lung cancer: clinical development and future directionsMET inhibition in lung cancer.Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance.Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism.Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer.Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression.A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer.Supramolecular aptamer nano-constructs for receptor-mediated targeting and light-triggered release of chemotherapeutics into cancer cells.
P2860
Q26799900-AB648C49-787E-4329-8195-6F9D4979F4EDQ33769429-567275C5-3F2D-4475-9ECD-40E53B7CB97BQ34254343-D3CA01FD-7049-4F9C-90A3-AEF5F2564F9CQ35117568-2D3FCCBA-3AE2-4400-A696-D0AF032E448FQ35866113-B4E576F9-39E0-4841-84B9-F20369968FC7Q35914680-F6EDA436-522E-476B-AF88-29DF78048F86Q36788312-BAB1DFA1-C911-4FFD-90A4-1C102285A13AQ37375274-7C8A406A-FCEA-4211-9782-53EA2DBAE348Q37597847-E582930E-AEBD-472B-A63A-F467F834921DQ37628915-A4328B55-35B6-4889-8E19-0936FA347B03Q37645240-C87FD7E7-F2C2-4CA4-B639-64D9D1ACE657Q38390016-9456642C-4CE3-4622-B608-2671752B5FABQ38809675-01EE92B1-75FF-49D9-A4B3-8D1C1EAAA1AAQ38811433-E2275A22-7DFE-4FA1-BE52-1FB10ECCC71AQ38956071-D8751874-4484-484E-8B5A-3020E72E7E51Q39001792-E1818E62-1636-4FC8-8C5B-9629D3A1C7EBQ42153446-632910AE-E958-4AEB-9B0D-17C16BEC035EQ47887010-E36F1412-48C8-41CB-8BD4-7A65AA480BBFQ49424319-8835366C-F472-4DD5-87FF-2D6CAA0FD126
P2860
Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Molecular predictors of sensit ...... 65752 in lung carcinoma cells.
@en
Molecular predictors of sensit ...... 65752 in lung carcinoma cells.
@nl
type
label
Molecular predictors of sensit ...... 65752 in lung carcinoma cells.
@en
Molecular predictors of sensit ...... 65752 in lung carcinoma cells.
@nl
prefLabel
Molecular predictors of sensit ...... 65752 in lung carcinoma cells.
@en
Molecular predictors of sensit ...... 65752 in lung carcinoma cells.
@nl
P2093
P1476
Molecular predictors of sensit ...... 65752 in lung carcinoma cells.
@en
P2093
Daisuke Matsubara
Hiroyuki Aburatani
Masashi Fukayama
Sachiko Oguni
Shumpei Ishikawa
Toshiro Niki
P304
P356
10.1097/JTO.0B013E3181E2A409
P577
2010-09-01T00:00:00Z